Centaurus Financial Inc. Purchases 289 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Centaurus Financial Inc. increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 18.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,858 shares of the pharmaceutical company’s stock after acquiring an additional 289 shares during the period. Centaurus Financial Inc.’s holdings in Vertex Pharmaceuticals were worth $864,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the company. Northwest Investment Counselors LLC bought a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter valued at about $25,000. Highline Wealth Partners LLC bought a new stake in Vertex Pharmaceuticals during the third quarter valued at approximately $27,000. GHP Investment Advisors Inc. purchased a new position in Vertex Pharmaceuticals in the 2nd quarter worth approximately $29,000. Stephens Consulting LLC bought a new position in shares of Vertex Pharmaceuticals in the 2nd quarter worth $31,000. Finally, Founders Capital Management raised its position in shares of Vertex Pharmaceuticals by 50.0% during the 2nd quarter. Founders Capital Management now owns 75 shares of the pharmaceutical company’s stock valued at $35,000 after buying an additional 25 shares in the last quarter. 90.96% of the stock is owned by institutional investors.

Insider Activity

In related news, Chairman Jeffrey M. Leiden sold 3,784 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $499.00, for a total transaction of $1,888,216.00. Following the sale, the chairman now owns 9,994 shares of the company’s stock, valued at $4,987,006. The trade was a 27.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Sangeeta N. Bhatia sold 646 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $500.00, for a total transaction of $323,000.00. Following the transaction, the director now directly owns 4,435 shares of the company’s stock, valued at $2,217,500. This represents a 12.71 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 4,445 shares of company stock worth $2,218,394. Corporate insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on VRTX. Raymond James reiterated a “market perform” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, October 10th. StockNews.com lowered Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 21st. UBS Group boosted their target price on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Morgan Stanley increased their price target on shares of Vertex Pharmaceuticals from $473.00 to $476.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Finally, Truist Financial restated a “buy” rating and issued a $550.00 price objective (up from $508.00) on shares of Vertex Pharmaceuticals in a report on Monday, August 5th. Three analysts have rated the stock with a sell rating, eight have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $504.38.

Vertex Pharmaceuticals Price Performance

VRTX stock opened at $461.71 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. Vertex Pharmaceuticals Incorporated has a 1 year low of $346.29 and a 1 year high of $519.88. The firm has a 50-day moving average of $473.55 and a 200 day moving average of $474.04. The company has a market cap of $118.90 billion, a P/E ratio of -232.02 and a beta of 0.39.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.77. The firm had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The business’s revenue was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.67 EPS. On average, sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.83 EPS for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.